

# PACE/PAP/CRDP Provider Bulletin

December 19, 2025

## Commonwealth of Pennsylvania Drug Manufacturers' Rebate Program Non-Participating Manufacturers

**The manufacturer labelers identified below will no longer have their products reimbursed by PACE, PAP, CRDP, and SPBP2 effective January 26, 2026.**

Providers using products from these manufacturers may wish to explore alternative sources.

Labeler Number	Drug Manufacturer Name	Medication(s) Affected
55494	Duchesnay USA, Inc.	Osphena®
60631	Azurity Pharmaceuticals, Inc.	Edarbi®, edarbyclor
73043	Devatis, Inc.	cyclosporine
82260	Bausch & Lomb Americas Inc.	loteprednol etabonate, bromfenac sodium, timolol maleate
83034	Verona Pharma, Inc.	Ohtuvayre
72078	Mylan Institutional	Meropenem
23155	AVET Pharmaceuticals, Heritage Pharmaceuticals	hydrochlorothiazide, methimazole, buspirone hcl, torsemide
58151	Viatris Specialty LLC	Dilantin®, Lyrica®, Effexor XR®, Norvasc®
83980	Unichem-Ipca Laboratories LTD	hydroxychloroquine sulfate, furosemide, propranolol hcl
73475	Argenx US Inc.	Vyvgart®

**Please direct any questions concerning this non-compliance decision to the appropriate manufacturer.**